Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab

Bruce E. Sands*, Richard Kozarek, Jack Spainhour, Charles F. Barish, Scott Becker, Lawrence Goldberg, Seymour Katz, Ronald Goldblum, Rena Harrigan, Eborah Hilton, Stephen B. Hanauer

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

121 Scopus citations


Background: Natalizumab, a humanized monoclonal IgG4 antibody to αA integrin, was investigated as a treatment of active Crohn's disease (CD). The safety of natalizumab given in combination with infliximab has not previously been studied. Methods: Seventy-nine adult patients with active CD (Crohn's Disease Activity Index [CDAI] score ≥ 150) despite ongoing infliximab treatment were randomized 2:1 to receive 3 intravenous infusions of natalizumab (300 mg; n = 52) or placebo (n = 27) every 4 weeks. Patients received infliximab (5 mg/kg) every 8 weeks for at least 10 weeks before randomization and throughout the study. The primary objective was to assess the short-term safety and tolerability of natalizumab in patients concurrently receiving infliximab. Secondary and tertiary objectives included measures of efficacy, health-related quality of life (HRQoL), and effects on inflammatory markers. A subset of patients also participated in a pharmacokinetic/ pharmacodynamic (PK/PD) analysis of the effects of concurrent treatment. Results: Incidence of adverse events (AEs) was similar in the treatment groups. AEs frequently reported in both groups were headache, CD exacerbation, nausea, and nasopharyngitis. No patient had a hypersensitivity-like reaction to natalizumab, whereas 4 patients (5%) experienced reactions to infliximab. Two patients (4%) developed anti-natalizumab antibodies; 10 patients (14%) developed anti-infliximab antibodies. The mean CDAI score decreased with natalizumab plus infliximab but was unchanged with infliximab alone (-37.7 versus +3.5; P = 0.084). Patients in both groups showed small increases in HRQoL (P = 0.811). No drug-drug interactions were noted. Conclusions: The combination of natalizumab plus infliximab was well tolerated. Several positive trends suggested that treating patients not in remission with infliximab plus natalizumab had greater efficacy than treatment with infliximab alone.

Original languageEnglish (US)
Pages (from-to)2-11
Number of pages10
JournalInflammatory bowel diseases
Issue number1
StatePublished - 2007


  • Combination therapy
  • Crohn's disease
  • Infliximab
  • Natalizumab
  • Randomized controlled trial

ASJC Scopus subject areas

  • Immunology and Allergy
  • Gastroenterology


Dive into the research topics of 'Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab'. Together they form a unique fingerprint.

Cite this